Accession Number : ADA335055

Title :   Improved 5-Fluorouracil Chemotherapy in Breast Cancer Patients by Monitoring Dihydropyrimidine Dehydrogenase Activity

Descriptive Note : Final rept 15 Aug 94-14 Aug 97

Corporate Author : ALABAMA UNIV IN BIRMINGHAM

Personal Author(s) : Lu, Zhihong

PDF Url : ADA335055

Report Date : SEP 1997

Pagination or Media Count : 34

Abstract : Dihydropyrimidine Dehydrogenase (DPD) is the initial, rate-limiting enzyme in catabolism of 5- fluorouracil (5-FU), one of the most widely used chemotherapeutic agents in the treatment of breast cancer. The purpose of this project is to improve 5-FU-based chemotherapy by monitoring DPD.

Descriptors :   *CHEMOTHERAPEUTIC AGENTS, *BREAST CANCER, PATIENTS, CATABOLISM, DEHYDROGENASES.

Subject Categories : Medicine and Medical Research
      Pharmacology

Distribution Statement : APPROVED FOR PUBLIC RELEASE